Jennifer JD - ACADIA Pharmaceuticals Chief VP
ACAD Stock | USD 17.05 0.03 0.18% |
VP
Jennifer JD is Chief VP of ACADIA Pharmaceuticals
Age | 54 |
Address | 12830 El Camino Real, San Diego, CA, United States, 92130 |
Phone | (858) 558-2871 |
Web | https://www.acadia.com |
ACADIA Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0686) % which means that it has lost $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1473) %, meaning that it created substantial loss on money invested by shareholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of May 6, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 41 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.6 M.Management Performance
Return On Equity | -0.15 | ||||
Return On Asset | -0.0686 |
ACADIA Pharmaceuticals Leadership Team
Elected by the shareholders, the ACADIA Pharmaceuticals' board of directors comprises two types of representatives: ACADIA Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACADIA. The board's role is to monitor ACADIA Pharmaceuticals' management team and ensure that shareholders' interests are well served. ACADIA Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ACADIA Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Parag PharmD, Senior Franchise | ||
Elizabeth Thompson, Executive Development | ||
Bob Mischler, Senior Strategy | ||
Albert Kildani, Senior Communications | ||
Douglas MD, Executive Development | ||
Stephen JD, CEO President | ||
James Kihara, Chief VP | ||
Jennifer JD, Chief VP | ||
Kimberly Manhard, Senior Execution | ||
Rob Ackles, Senior Officer | ||
Julie Fisher, Senior Strategy | ||
MSPH MD, President | ||
Holly Valdiviez, Senior Sales | ||
Brendan Teehan, COO VP | ||
Erika Zavod, Planning, Strategy | ||
Austin Kim, Executive Vice President General Counsel, Secretary | ||
Sanjeev MD, Senior Development | ||
Mark Schneyer, Executive CFO | ||
Kevin Oliver, Senior Officer | ||
Stephanie Kim, Senior Affairs | ||
Mark Johnson, Vice President Investor Relations | ||
Benir Ruano, Senior Operations | ||
MPH MD, Global SVP |
ACADIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ACADIA Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.15 | ||||
Return On Asset | -0.0686 | ||||
Profit Margin | (0.08) % | ||||
Operating Margin | 0.15 % | ||||
Current Valuation | 2.43 B | ||||
Shares Outstanding | 165.2 M | ||||
Shares Owned By Insiders | 0.47 % | ||||
Shares Owned By Institutions | 99.95 % | ||||
Number Of Shares Shorted | 11.16 M | ||||
Price To Earning | (13.77) X |
Pair Trading with ACADIA Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ACADIA Stock
0.73 | EGRX | Eagle Pharmaceuticals | PairCorr |
0.66 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against ACADIA Stock
0.79 | SNDL | SNDL Inc Financial Report 20th of May 2024 | PairCorr |
0.74 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
0.72 | QLI | Qilian International | PairCorr |
0.7 | IMCC | Im Cannabis Corp | PairCorr |
0.52 | PAHC | Phibro Animal Health Trending | PairCorr |
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.